title: [Treatment of central serous chorioretinopathy with beta blockers].
abstract: On a group of 13 eyes the authors evaluate their experience with medicamentous treatment of central serous chorioretinopathy. For treatment they used the non-selective beta-blocker Trimepranol, 2 x 5 mg/day. They found that in 11 eyes, in 84.6% cases, adherence of the ablated neuroepithelium of the macula occurred latest within four months of treatment, in two eyes (15.4%) this therapeutic dose did not lead to remission of the disease even after four months of treatment and the condition was evaluated as failure of treatment. The authors conclude that a therapeutic dose of Trimepranol of 2 x 5 mg/day is not a reliable therapeutic solution of central serous chorioretinopathy.
authors.affiliation: Ocní klinika FN a LF UP, Olomouc.
authors.forename: O
authors.initials: O
authors.lastname: Chrapek
authors.forename: K
authors.initials: K
authors.lastname: Spacková
authors.forename: J
authors.initials: J
authors.lastname: Rehák
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000328:Adult; D015862:Choroid Diseases / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D006801:Humans; D008297:Male; D014290:Metipranolol / Q000627:therapeutic use*; D012164:Retinal Diseases / Q000188:drug therapy* / Q000503:physiopathology; D014792:Visual Acuity
chemical_list: D000319:Adrenergic beta-Antagonists; D014290:Metipranolol